risk
target
coinhibitori
pathway
modul
pathogendirect
cell
respons
institut
microbiolog
eth
zurich
wolfgangpaulistr
zurich
switzerland
identif
cell
coinhibit
central
mechan
regul
adapt
immun
infecti
diseas
provid
new
opportun
immunotherapeut
intervent
howev
fact
cell
activ
frequent
downregul
pathogendirect
respons
suggest
pivot
physiolog
role
coinhibitori
pathway
infecti
diseas
report
exacerb
immunopatholog
condit
impair
coinhibit
foster
view
downregul
cell
activ
essenti
neg
feedback
mechan
protect
excess
pathogendirect
immun
thu
target
coinhibitori
pathway
bear
detriment
potenti
deregul
physiolog
process
summar
recent
preclin
clinic
intervent
report
immunerel
advers
event
target
coinhibitori
pathway
cell
coinhibitori
pathway
therapeut
target
cosign
essenti
compon
cell
activ
differenti
integr
costimulatori
inhibitori
signal
cell
receptor
engag
determin
function
capac
cell
immun
toler
sever
coinhibitori
receptor
immunoglobulin
superfamili
program
death
pd
cytotox
lymphocyteassoci
antigen
ctla
initi
identifi
crucial
establish
mainten
peripher
toler
due
suppress
selfreact
adapt
immun
respons
coinhibitori
receptor
also
assign
increas
relev
regul
immun
respons
alter
self
foreign
antigen
cancer
variou
tumor
exhibit
high
express
level
coinhibitori
ligand
correl
poor
prognosi
tumorinfiltr
cell
express
multipl
coinhibitori
receptor
compromis
tumorspecif
cell
respons
infect
coinhibitori
pathway
modul
cell
immun
major
class
pathogen
virus
bacteria
protozoa
fungi
nematod
parasit
howev
immunomodulatori
function
coinhibitori
pathway
extens
investig
context
persist
viru
infect
contribut
downregul
antivir
effector
function
view
accumul
studi
suggest
profound
role
cell
coinhibit
tumor
establish
pathogen
persist
interfer
coinhibitori
pathway
repres
promis
approach
enhanc
protect
immun
therefor
benefit
treatment
block
antibodi
target
coinhibitori
receptor
ligand
investig
numer
anim
model
clinic
studi
despit
document
therapeut
potenti
coinhibitori
pathway
interfer
variou
infecti
diseas
distinct
studi
report
advers
event
overal
detriment
consequ
interf
cell
coinhibit
tabl
line
report
find
suggest
vital
role
cell
coinhibit
protect
immunemedi
tissu
damag
persist
viru
infect
result
other
highlight
releas
neg
immunoregul
bear
consider
detriment
potenti
form
sever
immunopatholog
discuss
potenti
risk
factor
consider
therapeut
target
coinhibitori
pathway
infecti
diseas
suggest
therapeut
approach
take
account
biolog
pathogen
elicit
diseas
biolog
target
coinhibitori
pathway
well
specif
characterist
individu
treat
figur
despit
promis
preclin
result
studi
use
divers
type
pathogen
sever
aspect
pathogen
biolog
might
contraind
interfer
coinhibitori
pathway
exampl
program
death
ligand
pdl
blockad
prior
listeria
monocytogen
infect
neg
affect
antibacteri
cell
respons
suppress
suggest
result
increas
nitric
oxid
product
macrophag
blockad
macrophagederiv
hallmark
infect
intracellular
bacteria
blockad
might
also
compromis
cell
respons
intracellular
bacteria
accordingli
defici
signal
precipit
increas
mortal
infect
intracellular
bacterium
salmonella
typhimurium
mycobacterium
tuberculosi
increas
mortal
attribut
impair
helper
th
develop
former
immunopatholog
due
excess
respons
latter
infect
model
despit
diverg
impact
impair
coinhibit
immun
respons
elicit
intracellular
bacteria
share
protect
function
confer
signal
viral
infect
render
host
cell
target
cellmedi
kill
henc
viral
tropism
relev
interf
coinhibitori
pathway
blockad
cell
coinhibit
enhanc
cellular
cytotox
might
affect
vital
organ
function
due
enhanc
kill
infect
yet
indispens
cell
type
note
consider
relev
infect
noncytopath
virus
leav
infect
host
cell
viabl
furthermor
straindepend
variat
pathogen
virul
also
seem
impact
benefit
target
coinhibitori
pathway
although
blockad
infect
strain
plasmodium
yoelii
result
improv
parasit
clearanc
devoid
overt
immunopatholog
treat
mice
infect
virul
strain
pyleth
lead
exacerb
inflamm
increas
mortal
addit
pathogen
biolog
sever
infectionrel
paramet
consid
interf
coinhibitori
pathway
progress
persist
lymphocyt
choriomening
viru
lcmv
infect
decis
therapeut
impact
blockad
treatment
earli
infect
elicit
fatal
immunopatholog
wherea
treatment
establish
persist
infect
enhanc
antivir
cell
respons
without
develop
advers
event
moreov
blockad
without
effect
conduct
day
p
yoelii
strain
pyleth
infect
start
treatment
day
postinfect
significantli
increas
mortal
analog
blockad
day
l
monocytogen
infect
compromis
antibacteri
cell
immun
wherea
slight
delay
treatment
enhanc
antibacteri
cell
function
studi
highlight
diseas
progress
import
factor
coinhibitori
interfer
even
minor
chang
inject
schedul
render
treatment
ineffect
detriment
lcmv
model
system
also
suggest
extent
pathogen
dissemin
crucial
success
coinhibitori
pathway
blockad
mice
infect
rapidli
control
therefor
local
defin
low
inoculum
dose
lcmv
docil
remain
asymptomat
earli
blockad
contrast
highdos
infect
mice
viru
dissemin
system
succumb
lethal
immunopatholog
earli
blockad
studi
tuberculosi
infect
also
highlight
import
evalu
costimulatori
pathway
interfer
vivo
enhanc
effector
function
observ
vitro
human
cell
blockad
translat
fatal
immunopatholog
tuberculosisinfect
defici
mice
taken
togeth
pathogenspecif
factor
cell
tropism
strainspecif
virul
well
infectionrel
paramet
diseas
progress
pathogen
dissemin
determin
therapeut
benefit
coinhibitori
pathway
interfer
ligand
receptor
express
pattern
defin
physiolog
role
coinhibitori
pathway
pathogendirect
immun
respons
specif
cell
type
protect
nearbi
cell
cell
effector
function
upregul
coinhibitori
ligand
express
hepat
endotheli
kupffer
cell
report
inhibit
local
cell
effector
function
protect
aggrav
liver
patholog
adenoviru
infect
express
oligodendroglia
central
nervou
system
cn
demyelin
coronavirusinfect
mice
suppress
cell
effector
function
might
offer
protect
fatal
axon
bystand
damag
moreov
upregul
fibroblast
reticular
cell
dampen
destruct
splenic
architectur
persist
lcmv
infect
infect
model
cell
nonhematopoiet
origin
elicit
fatal
immunopatholog
day
infect
although
ligand
express
pattern
defin
type
local
protect
target
cell
coinhibitori
receptor
express
determin
cell
type
effector
function
subject
neg
regul
henc
interrupt
signal
specif
receptor
manifest
enhanc
effector
function
specif
cell
type
might
consid
design
therapeut
approach
immunopatholog
process
observ
lcmv
coronaviru
system
attribut
excess
pathogendirect
cell
respons
likewis
increas
mortal
blockad
virul
malaria
infect
result
increas
interferon
ifn
g
product
cell
herp
simplex
viru
hsv
tuberculosi
infect
impair
signal
lead
pathogen
proinflammatori
cytokin
secret
cell
also
blockad
increas
cell
expans
associ
significantli
enhanc
mortal
experiment
bloodstag
malaria
although
studi
focus
capac
cell
degranul
produc
ifng
elev
level
proinflammatori
mediat
tumor
necrosi
factor
tnf
interleukin
il
frequent
observ
system
treat
mice
conflict
result
publish
role
coinhibitori
receptor
develop
function
follicular
helper
tfh
cell
compromis
capac
tfh
cell
promot
germin
center
format
immun
nitrophenolchicken
gamma
globulin
npcgg
knockout
mice
exhibit
reduc
fecal
iga
level
due
skew
tfh
cell
cytokin
profil
gut
howev
mice
mount
enhanc
tfh
cell
humor
respons
schistosoma
mansoni
infect
simultan
blockad
lymphocyteactiv
gene
lag
boost
pathogenspecif
tfh
cell
igg
product
p
yoelii
infect
although
studi
share
posit
effect
impair
signal
total
number
tfh
cell
significantli
differ
respect
impact
antibodi
product
blockad
coinhibitori
pathway
might
also
impact
innat
immun
express
activ
natur
killer
nk
cell
lesser
degre
monocyt
myeloid
dendrit
cell
thu
impair
signal
might
also
enhanc
effector
function
innat
immun
cell
exacerb
patholog
mice
murin
hepat
viru
mhv
infect
could
driven
increas
ifng
secret
nk
cell
block
cell
immunoglobulin
mucin
earli
coxsackieviru
infect
decreas
express
level
costimulatori
molecul
macrophag
mast
cell
well
express
regulatori
cell
associ
aggrav
infectioninduc
inflammatori
heart
diseas
interf
receptorligand
interact
possibl
multipl
interact
partner
must
taken
account
one
receptor
interact
multipl
ligand
vice
versa
thu
block
strategi
could
elicit
sever
concert
mayb
even
oppos
effect
known
interact
well
turn
given
interact
exert
oppos
effect
pathogendirect
immun
respons
seen
leishmania
mexicana
trypanosoma
cruzi
infect
block
specif
ligand
might
prefer
target
receptor
order
achiev
desir
effect
likewis
tnf
receptor
famili
member
herpesviru
entri
mediat
hvem
known
interact
light
homolog
lymphotoxin
induc
express
compet
hsv
glycoprotein
hvem
receptor
express
lymphocyt
lymphotoxin
lt
b
lymphocyt
attenu
btla
interact
two
former
molecul
describ
costimulatori
wherea
two
latter
interact
coinhibitori
interact
hvem
light
pivot
clearanc
hepat
leishmania
donovani
infect
infect
model
bind
light
differ
receptor
ltbr
inhibit
parasitedirect
cell
respons
earli
infect
suggest
oppos
role
light
within
one
model
system
due
interact
distinct
molecul
interf
specif
costimulatori
pathway
narrow
therapeut
window
magnitud
enhanc
immun
respons
improv
pathogen
control
without
exceed
threshold
pathogen
concept
support
find
immunopatholog
less
sever
tuberculosisinfect
mice
mice
absenc
express
probabl
compens
ligand
therefor
lead
modest
increas
cell
respons
wherea
may
lead
stronger
releas
cell
inhibit
thu
sever
patholog
view
immunerel
advers
event
result
overeffect
releas
coinhibit
also
question
use
simultan
target
multipl
coinhibitori
pathway
inhibit
combin
immunostimulatori
treatment
although
promis
result
obtain
murin
model
system
persist
viral
infect
prophylact
vaccin
advers
event
report
treatment
human
hcvspecif
cell
block
antibodi
stimul
ex
vivo
partial
inhibit
cell
respons
due
overstimul
line
simultan
applic
block
highdos
agonist
antibodi
persist
lcmv
infect
lead
transient
enhanc
virusdirect
cell
respons
cell
overstimul
driven
apoptosi
furthermor
simian
immunodefici
viru
siv
infect
macaqu
combin
antiretrovir
therapi
simultan
blockad
indoleamin
ido
inhibit
elicit
lethal
pancreat
contrari
classic
function
coinhibitori
pathway
signal
stimul
sustain
pathogendirect
immun
respons
distinct
condit
contraind
interrupt
upregul
cell
prolong
cell
surviv
enhanc
protect
immun
ovalbumin
ova
immun
block
cell
vitro
prime
enhanc
product
ifng
turn
impair
cell
expans
due
increas
ifngdriven
secret
costimul
macrophag
moreov
defici
impair
respons
typhimurium
express
cell
requir
effici
dendrit
cell
matur
influenza
viru
infect
blockad
dendrit
cell
also
report
compromis
costimulatori
capac
acut
infect
wherea
blockad
macrophag
decreas
gener
thu
aggrav
parasitemia
cruzi
infect
cell
coinhibit
requir
establish
mainten
peripher
toler
therefor
possibl
interf
coinhibitori
pathway
impact
peripher
toler
although
remain
investig
detail
sever
studi
mostli
field
human
cancer
immunotherapi
provid
insight
clinic
evalu
blockad
patient
advancedstag
melanoma
shown
sever
immunerel
advers
event
ira
includ
enterocol
result
dysregul
intestin
immun
addit
ira
document
target
therapi
includ
endocrinopathi
nephriti
hepat
dermat
singl
dose
block
antibodi
elicit
inflammatori
coliti
hypothyroid
two
advanc
solid
tumor
patient
recent
data
trial
evalu
safeti
activ
blockad
larger
cohort
advanc
solid
tumor
patient
document
advers
event
potenti
immunerel
origin
includ
hypothyroid
hepat
diabet
mellitu
treat
individu
concurr
perform
studi
assess
analog
aspect
blockad
solid
tumor
patient
reproduc
ira
also
observ
coliti
pneumon
hypophys
thyroid
although
report
advers
event
categor
nonsever
illustr
potenti
temporari
pathway
blockad
break
immunolog
toler
trend
immunolog
may
vol
summari
coinhibitori
ligand
confer
pivot
protect
vital
cell
type
blockad
specif
receptor
releas
inhibit
distinct
effector
function
multipl
interact
partner
within
coinhibitorystimulatori
network
thu
inhibit
might
counteract
desir
effect
lead
advers
effect
treatment
approach
also
requir
take
account
narrow
therapeut
window
potenti
immunestimul
role
coinhibitori
pathway
indispens
maintain
peripher
toler
consid
pivot
role
coinhibitori
pathway
protect
excess
immun
patient
histori
genet
predisposit
specif
autoimmun
diseas
current
state
health
might
import
interf
coinhibit
defici
coinhibitori
signal
contribut
spontan
induc
develop
autoimmun
diseas
thu
certain
precondit
would
contraind
pathway
blockad
individu
prone
develop
suffer
diabet
could
experi
earli
onset
aggrav
diseas
report
treat
prediabet
nod
mice
likewis
patient
display
acut
chronic
inflammatori
diseas
exampl
intestin
joint
could
regard
highrisk
patient
view
coinhibitori
pathway
contribut
control
excess
inflamm
site
individu
atherosclerosi
increas
potenti
develop
inflammatori
disord
vascular
system
could
suffer
earli
onset
exacerb
diseas
similar
signalingdefici
mice
predispos
patholog
defect
signal
also
associ
progress
multipl
sclerosi
human
earli
onset
aggrav
experiment
autoimmun
encephalomyel
eae
mice
thu
individu
precondit
inflammatori
cn
patholog
may
addit
risk
data
rodent
model
suggest
coinhibitori
pathway
play
role
transplant
toler
therefor
contraind
coinhibitori
pathway
blockad
transplant
recipi
pathway
interfer
could
also
impact
superinfect
although
investig
detail
consid
high
preval
tuberculosi
superinfect
among
hivposit
individu
detriment
impact
diseas
sever
tuberculosi
mous
model
target
pathway
reinvigor
cell
respons
hiv
infect
might
induc
advers
immunopatholog
event
pathway
blockad
might
also
discontinu
case
influenza
viru
superinfect
impair
influenza
virusspecif
cell
respons
recent
studi
document
therapeut
effect
signal
blockad
persist
viru
infect
requir
protect
excess
immun
pathogen
escherichia
coli
streptococcu
pneumonia
infect
also
render
superinfect
latter
pathogen
pathway
blockad
tenuou
final
limit
insight
modulatori
role
coinhibitori
pathway
recal
respons
studi
secondari
lcmv
infect
summari
individu
prone
develop
autoimmun
suffer
acut
chronic
inflammatori
diseas
receiv
transplant
risk
treat
coinhibitiontarget
therapi
acquisit
superor
secondari
infect
pathway
blockad
might
bear
potenti
elicit
detriment
advers
event
clinic
set
infecti
diseas
blockad
coinhibitori
pathway
provok
signific
advers
event
consid
therapeut
approach
context
treat
local
infect
prefer
system
diseas
possibl
immunerel
side
effect
would
local
confin
easier
compens
antagon
reinvigor
downregul
adapt
immun
establish
chronic
infect
like
bear
lower
risk
provok
patholog
level
proinflammatori
cytokin
excess
kill
infect
cell
treat
acut
infect
peak
pathogendirect
immun
respons
due
reduc
number
antivir
cell
multipl
mechan
cell
downregul
present
establish
chronic
viral
infect
releas
coinhibit
could
safe
exploit
boost
antigenspecif
cell
respons
context
prophylact
therapeut
vaccin
furthermor
enhanc
pathogendirect
humor
respons
might
lower
propens
elicit
immunopatholog
antibodymedi
effector
mechan
involv
kill
autolog
cell
cancer
therapeut
target
coinhibit
boost
antitumor
immun
bear
low
risk
provok
excess
patholog
respons
rel
small
system
frequenc
tumorreact
cell
confin
respons
direct
tumor
environ
howev
precaut
taken
patient
suffer
chronic
inflammatori
diseas
acut
viral
infect
risk
longterm
treatment
releas
selfreact
cell
regul
consid
concept
coinhibitionmedi
protect
overshoot
pathogendirect
immun
respons
line
alreadi
recogn
physiolog
role
suppress
undesir
autoreact
cell
respons
therefor
like
coinhibit
adapt
immun
infecti
diseas
evolv
support
host
surviv
howev
excess
neg
regul
also
facilit
system
spread
persist
pathogen
end
ultim
goal
determin
coinhibit
overprotect
host
design
therapi
releas
diseasepromot
overprotect
without
elicit
immunopatholog
review
provid
framework
insight
protect
role
coinhibitori
pathway
infecti
diseas
highlight
consider
contraind
design
therapeut
approach
target
coinhibit
devoid
advers
event
trend
immunolog
may
vol
